Pre-made Indatuximab benchmark antibody ( Whole mAb ADC, anti-SDC1 therapeutic antibody, Anti-SDC/CD138/SYND1/syndecan Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Indatuximab biosimilar, Whole mAb ADC, Anti-SDC1 Antibody: Anti-SDC/CD138/SYND1/syndecan therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.
| Products Name (INN Index) | Pre-Made Indatuximab biosimilar, Whole mAb ADC, Anti-SDC1 Antibody: Anti-SDC/CD138/SYND1/syndecan therapeutic antibody |
|---|---|
| INN Name | Indatuximab |
| Target | SDC1 |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | Biotest AG |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Bladder cancer,Breast cancer,Multiple myeloma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SDC1 |
| Package |
